MedTrace Logo

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

NCT05298813 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2023-05-01

No results posted yet for this study

Summary

This is a Phase 1/2, randomized, double-blind, placebo-controlled, single-dose escalating-dose study in participants with mild to moderate COVID-19 illness.

Conditions

Interventions

BIOLOGICAL

IBIO123

IBIO123 1 mg, 5 mg and 10 mg

OTHER

Placebo

Matching Placebo

Sponsors & Collaborators

  • Immune Biosolutions Inc

    lead INDUSTRY

Principal Investigators

  • Sebastien Labbe, PhD · Immune Biosolutions

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2023-01-04
Completion
2023-01-04

Countries

  • Brazil
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05298813 on ClinicalTrials.gov